CORRECTED AMENDMENT

The following corrects the markings of the Amendment filed September 19, 2003, to comply with 37 C.F.R. § 1.173(b) and (d). This listing of claims will replace all prior versions and listing of claims:

1. (amended) A method for treating or reducing the predisposition to a condition selected from the group consisting of benign breast disease[,] or cancer of the prostate, [or elevated blood cholesterol,] said method comprising administering to a subject having said condition or predisposed to said condition a therapeutically effective amount of a health supplement composition comprising an extract from soya or clover, said composition comprising any two or more phytoestrogens of the group Genistein, Daidzein, Biochanin A, Formononetin or the natural glycosides of any of said phyto-estrogens.

2. (original) A method according to claim 1, wherein said composition is administered for treating benign breast disease.

3. (original) The method according to claim 1, wherein said phytoestrogen is extracted from soy.

4. (original) The method according to claim 3, wherein said phytoestrogen is extracted from soy hypocotyls.

5. (original) A method according to claim 1, wherein said phytoestrogen consists essentially of a) genistein and b) daidzein component, wherein component a) optionally contains biochanin A, and component b) optionally contains formononetin, and the ratio of a):b) is about 1:2 to 2:1.

6. (original) The method according to claim 1, wherein the phytoestrogen is administered in an amount of from about 20 mg to 200 mg per day.

7. (original) The method according to claim 1, wherein the phytoestrogen is administered in an amount of from about 50 mg to 150 mg per day.

8. (original) The method according to claim 1 whereby the phytoestrogen is administered at least daily, over a period of at least a month.

9. (canceled)

10. (original) A method according to claim 1, wherein said composition is administered for treating cancer of the prostate.

11. (amended) A pharmaceutical preparation, in solid dosage unit form, the biologically active component of said preparation [consisting essentially of] <u>comprising phytoestrogens consisting essentially of a) genistein and b) daidzein component, wherein component a) optionally contains biochanin A, and component b) optionally contains formononetin, and the ratio of a):b) is about 1:2 to 2:1</u> [any two or more concentrated, phytoestrogen-derived isoflavones selected from the group consisting of Genistein, Daidzein, Biochanin A, Formononetin] or the natural glycosides of any of said phytoestrogens and said preparation including a pharmaceutically acceptable carrier.

12. (original) A pharmaceutical preparation, as claimed in claim 11, wherein said solid dosage unit is selected from the group consisting of a pill, tablet, coated tablet, capsule or powder.

13. (original) A pharmaceutical preparation, as claimed in claim 12, wherein said isoflavone is present in said solid dosage unit in an amount from about 20 mg. to about 200 mg. per dosage unit.

14. (new) The pharmaceutical preparation according to claim 11, wherein said phyto-estrogen is extracted from soy.

15. (new) The pharmaceutical preparation according to claim 14, wherein said phyto-estrogen is extracted from soy hypocotyls.

16. (new) A method for treating or reducing the predisposition to a condition selected from the group consisting of benign breast disease, cancer of the prostate, or elevated blood cholesterol, said method comprising administering to a subject having said condition or predisposed to said condition a therapeutically effective amount of a health supplement composition comprising an extract from soy or clover, said composition comprising phytoestrogens, wherein the phytoestrogen consists essentially of (a) genistein and (b) daidzein, wherein component (a) optionally contains biochanin A, and component (b) optionally contains formononetin, wherein the ratio of (a):(b) is about 1:2 to 2:1.

17. (new) The method according to claim 16, wherein the phytoestrogen is administered in an amount of from about 20 mg to 200 mg per day.

18. (new) The method according to claim 16, wherein the phytoestrogen is administered in an amount of from about 50 mg to 150 mg per day.

19. (new) The method according to claim 16 whereby the phytoestrogen is administered at least daily, over a period of at least a month.